HLN Stock Risk & Deep Value Analysis
Haleon PLC
DVR Score
out of 10
What You Need to Know About HLN Stock
We analyzed Haleon PLC using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran HLN through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
Get notified when HLN moves
Same alert types as Telegram — presets or custom thresholds in your 🔔 feed.
📈HLN Performance Overview3yr weekly
Unlock HLN Performance Chart
See 3 years of price history, quarterly revenue trends, and DVR score changes
Weekly adjusted close · Quarterly revenue & EPS · DVR score history
HLN Risk Analysis & Red Flags
What Could Go Wrong
Weakening consumer demand for discretionary health products due to persistent macroeconomic headwinds or increased competition from private label brands could compress Haleon's already modest organic revenue growth (Q1 2026 +2.2%) and impede progress on debt reduction goals, leading to a downgrade in operating profit growth forecasts from the reaffirmed high single-digit target for FY26.
Risk Matrix
Overall
Moderate
Financial
Medium
Market
Medium
Competitive
Medium
Execution
Medium
Regulatory
Low
Red Flags
- ⚠
Low Organic Growth: Q1 2026 organic revenue growth of +2.2% is insufficient for a '10x potential' investment thesis.
- ⚠
Mature Market Positioning: Operates in generally mature consumer health segments, limiting opportunities for exponential market share gains.
- ⚠
High Market Capitalization: Current market cap of $29.52B implies significant appreciation needed for 10x, making it a statistical outlier for this growth profile.
- ⚠
Revenue Miss: Q1 2026 revenue missed estimates by -0.5%, indicating a slight challenge in meeting analyst expectations even in a stable business.
Upcoming Risk Events
- 📅
Weak Cold & Flu Season (Q4 2026/Q1 2027): A repeat of a weak cold & flu season could significantly depress organic revenue growth for a key category (as observed in Q1 2026), leading to missed revenue targets.
- 📅
Macroeconomic Headwinds (ongoing): Persistent inflation and rising interest rates could reduce consumer discretionary spending on Haleon's products or increase the company's borrowing costs, impacting 'high single-digit operating profit growth' guidance.
When to Reconsider
- 🚪
Exit if quarterly organic revenue growth falls below 1.0% for two consecutive quarters, indicating significant market share loss or demand destruction.
- 🚪
Sell if Net Debt/Adjusted EBITDA ratio exceeds 3.5x (current target <3.0x), signaling a deterioration in financial leverage.
- 🚪
Exit if management rescinds or significantly lowers FY26 high single-digit operating profit growth guidance.
Unlock HLN Risk Analysis & Red Flags
Create a free account to see the full analysis
Investment Thesis
If Haleon consistently achieves its high single-digit operating profit growth targets and further de-leverages its balance sheet towards a Net Debt/Adjusted EBITDA ratio below 3.0x, then its defensive earnings power, strong brand portfolio, and ongoing capital return via share buybacks will attract stable, income-focused institutional investors, leading to a modest valuation re-rating closer to best-in-class consumer health peers over the next 12-24 months. This is NOT an investment thesis for 10x growth, but rather for stability and modest appreciation.
Is HLN Stock Undervalued?
Unlock the full AI analysis for HLN
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
HLN Price Targets & Strategy
12-Month Target
$9.50
Bull Case
$11.00
Bear Case
$7.50
Valuation Basis
Based on 32x forward P/E applied to estimated $0.29 FY26 EPS, reflecting modest growth and current peer multiples for stable consumer healthcare.
Entry Strategy
Consider dollar-cost averaging in the $8.50-$9.00 range, especially on any market dips, as the stock typically finds support around its current valuation given its defensive characteristics.
Exit Strategy
Consider profit-taking if the stock approaches $10.50-$11.00, representing a reasonable premium. Set a stop-loss at $7.50, below recent consolidation areas, indicating potential fundamental weakness or market downturn.
Portfolio Allocation
2% for moderate risk tolerance (for defensive diversification, not high growth). This stock is not suitable for aggressive growth portfolios targeting 10x.
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is HLN Financially Healthy?
Valuation
P/E Ratio
17.50
Forward P/E
15.99
EV/EBITDA
10.33
PEG Ratio
2.04
Price/Book
1.84
Price/Sales
2.75
Profitability
Gross Margin
64.69%
Operating Margin
21.87%
Net Margin
15.11%
Return on Equity
10.30%
Revenue Growth
-1.81%
EPS
$0.18
Balance Sheet
Current Ratio
0.92
Quick Ratio
0.69
Debt/Equity
0.52
Cash Flow
EBITDA
$3.74B
Other
Beta (Volatility)
0.42
Dividend Yield
2.13%
Does HLN Have a Competitive Moat?
Sign in to unlockMoat Rating
🏰 Wide
Moat Trend
Stable
Moat Sources
3 Identified
Haleon's moat is robust, primarily driven by its portfolio of highly trusted, established brands that benefit from strong consumer loyalty and significant marketing investment. Its global distribution network and R&D capabilities further entrench its position, making it difficult for new entrants or smaller competitors to replicate its scale and reach for the foreseeable future.
Moat Erosion Risks
- •Increased Private Label Competition: Growing market penetration by private label brands in mature categories could erode pricing power and market share.
- •Changing Consumer Preferences: A significant shift in consumer health trends (e.g., away from traditional OTC to alternative remedies) could reduce demand for core products.
HLN Competitive Moat Analysis
Sign up to see competitive advantages
HLN Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral (Consistent with a stable, large-cap consumer healthcare stock, typically less subject to viral retail investor interest).
Institutional Sentiment
Neutral (No specific analyst upgrades/downgrades or target changes provided in research; general sentiment for such companies is often stable 'Hold' ratings).
Insider Activity (Form 4)
None identified in the supplied sources for the last 90 days. This indicates a lack of significant insider conviction (positive or negative) to re-rate the stock.
Options Flow
Normal options activity (No unusual put/call ratio or large block trades identified in the supplied sources, suggesting no significant institutional positioning changes).
Earnings Intelligence
Next Earnings
Estimated late July/early August 2026 (for Q2 2026)
Surprise Probability
Low (Given modest growth and Q1 slight miss, surprises are less likely for a stable, mature company).
Historical Earnings Pattern
Likely stable, with the stock reacting modestly to earnings reports, typically moving within a narrow range (e.g., +/- 2-5%) based on performance relative to guidance and any shifts in outlook.
Key Metrics to Watch
Competitive Position
Top Competitor
Kenvue (KVUE)
Market Share Trend
Stable overall, with specific strengths and gaining ground in categories like Oral Health (e.g., Sensodyne, parodontax showing double-digit growth in Q1 2026) while facing headwinds in others like Cold & Flu.
Valuation vs Peers
Trading broadly in line with or at a slight discount to mature consumer health peers like Kenvue on P/E and EV/EBITDA multiples, partially due to its recent spin-off status and debt levels.
Competitive Advantages
- •Strong Brand Power: Portfolio of globally recognized and trusted brands (e.g., Sensodyne, Advil, Centrum, Panadol).
- •Extensive Global Distribution: Access to a vast network of pharmacies, supermarkets, and online channels worldwide.
- •R&D & Innovation: Continued investment in product innovation and scientific differentiation within consumer healthcare.
- •Economies of Scale: Large-scale manufacturing and procurement provide cost advantages.
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
Earnings Call Report
Latest quarter — transcript highlights, guidance, and DVR overlay
Plain-language summary, key numbers, segment breakdown, and bull/bear signals from the most recent earnings call.
HLN Latest Earnings Call Breakdown
Sign up free, then upgrade to Premium to read the latest earnings call breakdown on stock reports.
What Could Drive HLN Stock Higher?
Near-Term (0-6 months)
- •Q2 2026 Earnings Report (est. late July/early August 2026): Stronger-than-expected organic revenue growth, especially in North America or oral health, could signal improved competitive positioning.
- •Continued Share Buyback Program (ongoing): Further significant share repurchases and cancellations, beyond the 18M+ shares in Apr-May 2026, could provide marginal EPS accretion and signal management's confidence.
Medium-Term (6-18 months)
- •Debt Reduction Milestones (FY26-FY27): Achieving the stated target of Net Debt/Adjusted EBITDA below 3.0x by end-2026 (from training data) would improve financial flexibility and potentially attract more stable institutional investment.
- •New Product Launches/Geographic Expansion (ongoing over 6-18 months): Successful launches of new products within existing categories (e.g., pain relief, vitamins) or expansion into under-penetrated emerging markets could add incremental revenue, particularly if exceeding 5% organic growth in key categories.
Long-Term (18+ months)
- •Consolidation & Portfolio Optimization (18-36 months): If Haleon engages in strategic divestitures of non-core assets or tuck-in acquisitions that enhance its leadership in high-margin categories, it could streamline operations and improve overall profitability towards a 15% operating margin.
- •Increased Market Share in Oral Health (3-5 years): If Sensodyne and parodontax continue double-digit growth and collectively capture an additional 2-3% market share in the global oral care market, it could contribute an additional £300-£500M in annual revenue, strengthening the company’s long-term competitive moat.
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for HLN?
- ✓
Watch quarterly organic revenue growth: Sustained acceleration above 3-4% could signal unexpected market gains.
- ✓
Monitor Net Debt/Adjusted EBITDA ratio: A consistent decline towards and below 2.5x would significantly strengthen the balance sheet.
- ✓
Observe any changes in FY26 operating profit growth guidance: A downgrade would indicate deteriorating fundamentals.
Bull Case Analysis
Sign up free to see the bull case
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Haleon PLC Makes Money
Haleon PLC is a global consumer healthcare company that develops, manufactures, and markets a wide range of everyday health products. It helps millions of people feel better and live healthier lives through well-known brands across Oral Health, Pain Relief, Vitamins/Minerals/Supplements, Respiratory, and Digestive Health. Essentially, it sells non-prescription medicines and health products directly to consumers through retail channels worldwide.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Haleon PLC (HLN)?
As of May 18, 2026, Haleon PLC has a DVR Score of 2.0 out of 10, placing it in the "Risk Trap" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Haleon PLC?
Haleon PLC's market capitalization is approximately $29.2B..
What is the risk level for HLN stock?
Our analysis rates Haleon PLC's overall risk as Moderate. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of HLN?
Haleon PLC currently has a price-to-earnings (P/E) ratio of 17.5. This is in line with broader market averages.
Does Haleon PLC pay a dividend?
Yes, Haleon PLC pays a dividend with a current yield of approximately 2.13%.
Is Haleon PLC's revenue growing?
Haleon PLC has reported revenue growth of -1.8%. Revenue has been declining, which warrants closer examination.
Is HLN stock profitable?
Haleon PLC has a profit margin of 15.1%. The company is profitable but margins are modest.
How often is the HLN DVR analysis updated?
Our AI-powered analysis of Haleon PLC is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on May 18, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for HLN (Haleon PLC) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.